Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sun Yat-sen Univ. HSF1 compound 1168
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
01
Overview
Sun Yat-sen Univ. HSF1 compound 1168: sourced facts only. name: "Collectively, these findings identify 1168 as a direct HSF1-DBD-binding inhibitor and establish borylated aza-arenes as a promising chemotype for the development of HSF1-targeted anticancer agents." [PMID:42275931]; target: "Collectively, these findings identify 1168 as a direct HSF1-DBD-binding inhibitor and establish borylated aza-arenes as a promising chemotype for the development of HSF1-targeted anticancer agents." [PMID:42275931]; developer: "School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China." [PMID:42275931]
02
Targets
HSF1 (Heat shock factor protein 1)
Beyond the preview
Go deeper on Sun Yat-sen Univ. HSF1 compound 1168.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Yat-sen Univ. HSF1 compound 1168.